Clinical trial
3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining…
NCT00275444 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00275444 |
|---|---|
| Title | 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study |
| Official title | Double-blind, Randomized, Dose Optimization Trial of Three Doses of Tipranavir Boosted With Low Dose Ritonavir (TPV/RTV) in Multiple Antiretroviral Drug-experienced Subjects |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Tipranavir |
| Enrollment | 216 |
| Start date | Mar 29, 2002 |
| Primary completion | Jan 20, 2003 |
| First posted | Jan 12, 2006 |
| Last update posted | Dec 1, 2023 |
| Countries | Australia, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: